Pionyr Immunotherapeutics
Immunotherapeutic approach that depletes immunosuppressive myeloid cells in the tumor microenvironment
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2015
- Latest Form D
- $7M, Apr 2018
- Total capital
- $45M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $45M
- 2 Form D · last Apr 2018
- 103 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 19 pending · first 2019
- Rank in peer group#269 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$7M
- Private capital raisedForm D · SEC · 1st filing$38M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#269 · top 19%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Carol F. GallagherDirectorNamed in SEC Form D filings
- Joshua F. Resnick, M.D.DirectorNamed in SEC Form D filings
- Leon F. Chen, Ph.D.DirectorNamed in SEC Form D filings
- Matthew F. Krummel, Ph.D.DirectorNamed in SEC Form D filings
- Michael F. PowellDirectorNamed in SEC Form D filings
- Steven P. JamesExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 24- PendingANTI-TREM1 Antibodies And Related MethodsUSPTOApplication 18767771
- PendingFibrosis Treatment With ANTI-TREM2 AntibodiesUSPTOApplication 18676059
- GrantedANTI-TREM1 Antibodies And Related MethodsUSPTOUS 12,065,491
Show all 24 patent records
- ANTI-TREM1 Antibodies And Related MethodsJun 5, 2025 · Application 18767771Pending
- Fibrosis Treatment With ANTI-TREM2 AntibodiesSep 12, 2024 · Application 18676059Pending
- ANTI-TREM1 Antibodies And Related MethodsAug 20, 2024 · US 12,065,491Granted
- Compositions And Methods For Disabling Myeloid Cells Expressing TREM1Apr 18, 2024 · Application 18361780Pending
- Anti-MARCO Antibodies and Uses ThereofFeb 7, 2023 · US 11,572,407Granted
- ANTI-TREM2 Antibodies And Related MethodsNov 22, 2022 · US 11,505,602Granted
- ANTI-TREM1 Antibodies And Related MethodsNov 17, 2020 · US 10,836,828Granted
- Compositions And Methods For Disabling Myeloid Cells Expressing TREM1Aug 6, 2020 · Application 16637421Pending
- ANTI-TREM2 Antibodies And Related MethodsDec 17, 2019 · US 10,508,148Granted
- ANTI-TREM2 Antibodies And Related MethodsApplication 62889990Pending
- ANTI-TREM1 Antibodies And Related MethodsApplication 62802161Pending
- ANTI-TREM2 Antibodies And Related MethodsApplication PCTUS2018065026Pending
- Compositions And Methods For Disabling Meyloid Cells Expressing TREM1Application PCTUS2018045680Pending
- Humanized Anti-TREM2 Antibodies and Related MethodsApplication 62648089Pending
- Humanized Anti-TREM2 Antibodies and Related MethodsApplication 62597827Pending
- Compositions and Methods for Disabling Non-Stimulatory Myeloid Cells Expressing TREM1Application 62542563Pending
- Fibrosis Treatment With ANTI-TREM2 AntibodiesApplication PCTUS2022080560Pending
- Fibrosis Treatment With ANTI-TREM2 AntibodiesApplication 63283738Pending
- Anti-marco Antibodies And Uses ThereofApplication PCTUS2021059955Pending
- Anti-MARCO Antibodies and Uses ThereofApplication 63244662Pending
- Anti-MARCO Antibodies and Uses ThereofApplication 63115272Pending
- ANTI-TREM1 Antibodies And Related MethodsApplication PCTUS2020016949Pending
- Methods Of Using ANTI-TREM2 AntibodiesApplication PCTUS2019065743Pending
- ANTI-TREM1 Antibodies And Related MethodsApplication 62889994Pending
Related companies, and why
- XGENOMES CORP.Similar federal contract value in Biotech · null in contracts
- SynlogicSimilar federal contract value in Biotech · null in contracts
- Akero TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Nkarta, Inc.Similar federal contract value in Biotech · null in contracts
- GLOBEIMMUNE INCSimilar federal contract value in Biotech · null in contracts
- Liquid BioScience, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .